{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:16:09Z","timestamp":1792271769836,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T00:00:00Z","timestamp":1551744000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00296-019-04269-w","type":"journal-article","created":{"date-parts":[[2019,3,5]],"date-time":"2019-03-05T22:51:18Z","timestamp":1551826278000},"page":"933-941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1079-4989","authenticated-orcid":false,"given":"Han Jie","family":"Soh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-2085","authenticated-orcid":false,"given":"Courtney","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5153-3171","authenticated-orcid":false,"given":"Victoria","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9631-4455","authenticated-orcid":false,"given":"William Douglas","family":"Renton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5221-8517","authenticated-orcid":false,"given":"Angela","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3018-2194","authenticated-orcid":false,"given":"Jane","family":"Munro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,5]]},"reference":[{"key":"4269_CR1","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1586\/17469872.2.6.775","volume":"2","author":"U Wollina","year":"2007","unstructured":"Wollina U, Buslau M, Petrov I, Pramatarov K (2007) Disabling pansclerotic morphea of childhood. Expert Rev Dermatol 2:775\u2013784","journal-title":"Expert Rev Dermatol"},{"key":"4269_CR2","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1001\/archderm.1980.01640260045011","volume":"116","author":"JL Diaz Perez","year":"1980","unstructured":"Diaz Perez JL, Connolly SM, Winkelmann RK (1980) Disabling pansclerotic morphea of children. Arch Dermatol 116:169\u2013173","journal-title":"Arch Dermatol"},{"key":"4269_CR3","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4103\/2229-5178.131092","volume":"5","author":"MK Dasgupta","year":"2014","unstructured":"Dasgupta MK, Patra C, Sarkar S, Das S (2014) Pansclerotic morphea: a male child with hemiatrophy of lower limb. Indian Dermatol Online J 5:170\u2013172","journal-title":"Indian Dermatol Online J"},{"key":"4269_CR4","first-page":"348","volume":"1","author":"AM Forsea","year":"2008","unstructured":"Forsea AM, Cretu AN, Ionescu R, Giurcaneanu C (2008) Disabling pansclerotic morphea of childhood\u2014unusual case and management challenges. J Med Life 1:348\u2013354","journal-title":"J Med Life"},{"key":"4269_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4103\/0019-5154.108079","volume":"58","author":"M Kura","year":"2013","unstructured":"Kura M, Jindal S (2013) Disabling pansclerotic morphea of childhood with extracutaneous manifestations. Indian J Dermatol 58:159","journal-title":"Indian J Dermatol"},{"key":"4269_CR6","first-page":"2538","volume":"33","author":"R Roldan","year":"2006","unstructured":"Roldan R, Morote G, Castro MDC, Miranda MD, Moreno JC, Collantes E (2006) Efficacy of bosentan in treatment of unresponsive cutaneous ulceration in disabling pansclerotic morphea in children. J Rheumatol 33:2538\u20132540","journal-title":"J Rheumatol"},{"key":"4269_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1046\/j.1525-1470.1999.00153.x","volume":"16","author":"U Wollina","year":"1999","unstructured":"Wollina U, Looks A, Uhlemann C, Wollina K (1999) Pansclerotic morphea of childhood-follow-up over 6 years. Pediatr Dermatol 16:245\u2013247","journal-title":"Pediatr Dermatol"},{"key":"4269_CR8","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1525-1470.2002.00033.x","volume":"19","author":"U Wollina","year":"2002","unstructured":"Wollina U, Buslau M, Weyers W (2002) Squamous cell carcinoma in pansclerotic morphea of childhood. Pediatr Dermatol 19:151\u2013154","journal-title":"Pediatr Dermatol"},{"key":"4269_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1525-1470.2008.00823.x","volume":"26","author":"I Petrov","year":"2009","unstructured":"Petrov I, Gantcheva M, Miteva L, Vassileva S, Pramatarov K (2009) Lower lip squamous cell carcinoma in disabling pansclerotic morphea of childhood. Pediatr Dermatol 26:59\u201361","journal-title":"Pediatr Dermatol"},{"key":"4269_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1046\/j.1365-2230.1998.00378.x","volume":"23","author":"U Wollina","year":"1998","unstructured":"Wollina U, Looks A, Schneider R, Maak B (1998) Disabling morphoea of childhood\u2014beneficial effect of intravenous immunoglobulin therapy. Clin Exp Dermatol 23:292\u2013293","journal-title":"Clin Exp Dermatol"},{"key":"4269_CR11","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00296-001-0150-2","volume":"21","author":"Devidayal","year":"2002","unstructured":"Devidayal, Singh S, Kumar L, Radotra B (2002) Disabling pansclerotic morphea of childhood and hypogammaglobulinemia: a curious association. Rheumatol Int 21:158\u2013160","journal-title":"Rheumatol Int"},{"key":"4269_CR12","first-page":"211","volume":"106","author":"G Martini","year":"2017","unstructured":"Martini G, Campus S, Raffeiner B, Boscarol G, Meneghel A, Zulian F (2017) Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases? Clin Exp Rheumatol Suppl 106:211\u2013213","journal-title":"Clin Exp Rheumatol Suppl"},{"key":"4269_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1346-8138.2003.tb00446.x","volume":"30","author":"M Yildirim","year":"2003","unstructured":"Yildirim M, Baysal V, Aridogan BC, Kesici D, Erturan I (2003) Pansclerotic morphea treated with UVA: a case report. J Dermatol 30:625\u2013627","journal-title":"J Dermatol"},{"key":"4269_CR14","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/art.30264","volume":"63","author":"F Zulian","year":"2011","unstructured":"Zulian F, Martini G, Vallongo C, Vittadello F, Falcini F, Patrizi A, Alessio M, La Torre F, Podda RA, Gerloni V, Cutrone M, Belloni-Fortina A, Paradisi M, Martino S, Perilongo G (2011) Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 63:1998\u20132006","journal-title":"Arthritis Rheum"},{"key":"4269_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3899\/jrheum.110210","volume":"39","author":"KS Torok","year":"2012","unstructured":"Torok KS, Arkachaisri T (2012) Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol 39:286\u2013294","journal-title":"J Rheumatol"},{"key":"4269_CR16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","volume":"64","author":"SC Li","year":"2012","unstructured":"Li SC, Torok KS, Pope E, Dedeoglu F, Hong S, Jacobe HT, Rabinovich CE, Laxer RM, Higgins GC, Ferguson PJ, Lasky A, Baszis K, Becker M, Campillo S, Cartwright V, Cidon M, Inman CJ, Jerath R, O\u2019Neil KM, Vora S, Zeft A, Wallace CA, Ilowite NT, Fuhlbrigge RC (2012) Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res 64:1175\u20131185","journal-title":"Arthritis Care Res"},{"key":"4269_CR17","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1177\/1534734607308731","volume":"6","author":"U Wollina","year":"2007","unstructured":"Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriopoulou E, Koch A, Kostler E, Schonlebe J, Haroske G, Doede T, Pramatarov K (2007) Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma. Int J Low Extremity Wounds 6:291\u2013298","journal-title":"Int J Low Extremity Wounds"},{"key":"4269_CR18","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/pde.12279","volume":"31","author":"A Odhav","year":"2014","unstructured":"Odhav A, Hoeltzel MF, Canty K (2014) Pansclerotic morphea with features of eosinophilic fasciitis: distinct entities or part of a continuum? Pediatr Dermatol 31:e42\u2013e47","journal-title":"Pediatr Dermatol"},{"key":"4269_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3899\/jrheum.090708","volume":"37","author":"SC Li","year":"2010","unstructured":"Li SC, Feldman BM, Higgins GC, Haines KA, Punaro MG, O\u2019Neil KM (2010) Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists. J Rheumatol 37:175\u2013181","journal-title":"J Rheumatol"},{"key":"4269_CR20","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/j.1365-2133.1995.tb00738.x","volume":"132","author":"K Scharffetter-Kochanek","year":"1995","unstructured":"Scharffetter-Kochanek K, Goldermann R, Lehmann P, Holzle E, Goerz G (1995) PUVA therapy in disabling pansclerotic morphoea of children. Br J Dermatol 132:830\u2013831","journal-title":"Br J Dermatol"},{"key":"4269_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1046\/j.1365-2133.1998.02060.x","volume":"138","author":"DJ Todd","year":"1998","unstructured":"Todd DJ, Askari A, Ektaish F (1998) PUVA therapy for disabling pansclerotic morphoea of children. Br J Dermatol 138:201\u2013202","journal-title":"Br J Dermatol"},{"key":"4269_CR22","first-page":"495","volume":"17","author":"MP Iqbal","year":"2007","unstructured":"Iqbal MP, Bajaj DR (2007) Disabling pansclerotic and plaque morphoea. J Coll Phys Surg Pak 17:495\u2013496","journal-title":"J Coll Phys Surg Pak"},{"key":"4269_CR23","doi-asserted-by":"publisher","first-page":"P77","DOI":"10.1186\/1546-0096-9-S1-P77","volume":"9","author":"M Moll","year":"2011","unstructured":"Moll M, Holzer U, Zimmer C, Rieber N, Kuemmerle-Deschner JB (2011) Autologous stem cell transplantation in two children with disabling pansclerotic morphea. Pediatr Rheumatol Online J 9:P77","journal-title":"Pediatr Rheumatol Online J"},{"key":"4269_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.jdcr.2017.12.003","volume":"4","author":"SR Kim","year":"2018","unstructured":"Kim SR, Charos A, Damsky W, Heald P, Girardi M, King BA (2018) Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib. JAAD Case Rep 4:443\u2013445","journal-title":"JAAD Case Rep"},{"key":"4269_CR25","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1111\/bjd.15593","volume":"177","author":"C Hurabielle","year":"2017","unstructured":"Hurabielle C, Sicre de Fontbrune F, Moins-Teisserenc H, Robin M, Jachiet M, Coman T, Dhedin N, Cassius C, Chasset F, De Masson A, Michonneau D, Bagot M, Bergeron A, Socie G, Peffault De Latour R, Bouaziz JD (2017) Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic graft-versus-host disease. Br J Dermatol 177:e206\u2013e208","journal-title":"Br J Dermatol"},{"key":"4269_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3899\/jrheum.130029","volume":"41","author":"A Kim","year":"2014","unstructured":"Kim A, Marinkovich N, Vasquez R, Jacobe HT (2014) Clinical features of patients with morphea and the pansclerotic subtype: a cross-sectional study from the morphea in adults and children cohort. J Rheumatol 41:106\u2013112","journal-title":"J Rheumatol"},{"key":"4269_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-222132","author":"I Jamalpur","year":"2018","unstructured":"Jamalpur I, Mogili HR, Koratala A (2018) Disabling pansclerotic morphoea of childhood. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2017-222132","journal-title":"BMJ Case Rep"},{"key":"4269_CR28","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1046\/j.1525-1470.2002.00235.x","volume":"19","author":"XH Nguyen","year":"2002","unstructured":"Nguyen XH, Hansen R, Valencia F (2002) Severe ankle deformity secondary to pansclerotic morphea in a 9-year-old girl: correction involving arthrodesis and free flap coverage. Pediatr Dermatol 19:560\u2013563","journal-title":"Pediatr Dermatol"},{"key":"4269_CR29","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11926-010-0142-x","volume":"13","author":"N Iwamoto","year":"2011","unstructured":"Iwamoto N, Distler JHW, Distler O (2011) Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials. Curr Rheumatol Rep 13:21\u201327","journal-title":"Curr Rheumatol Rep"},{"key":"4269_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/1744666X.2017.1263153","volume":"13","author":"C Bruni","year":"2017","unstructured":"Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, Matucci-Cerinic M (2017) Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol 13:469\u2013482","journal-title":"Expert Rev Clin Immunol"},{"key":"4269_CR31","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","volume":"48","author":"G Martini","year":"2009","unstructured":"Martini G, Ramanan AV, Falcini F, Girschick H, Goldsmith DP, Zulian F (2009) Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil. Rheumatology 48:1410\u20131413","journal-title":"Rheumatology"},{"key":"4269_CR32","doi-asserted-by":"publisher","first-page":"ii111","DOI":"10.1136\/annrheumdis-2012-202576","volume":"72","author":"JJ O\u2019Shea","year":"2013","unstructured":"O\u2019Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 72:ii111\u2013ii1115","journal-title":"Ann Rheum Dis"},{"key":"4269_CR33","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.4076\/1757-1626-2-6609","volume":"6","author":"N Tzaribachev","year":"2009","unstructured":"Tzaribachev N, Koetter I, Kuemmerle-Deschner JB, Schedel J (2009) Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series. Cases J 6:6609","journal-title":"Cases J"},{"key":"4269_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bbmt.2017.10.006","volume":"24","author":"KPA MacDonald","year":"2018","unstructured":"MacDonald KPA, Betts BC, Couriel D (2018) Emerging therapeutics for the control of chronic graft-versus-host disease. Biol Blood Marrow Transplant 24:19\u201326","journal-title":"Biol Blood Marrow Transplant"},{"key":"4269_CR35","doi-asserted-by":"publisher","first-page":"305","DOI":"10.5114\/reum.2017.72628","volume":"55","author":"J Narbutt","year":"2017","unstructured":"Narbutt J, Ho\u0142drowicz A, Lesiak A (2017) Morphea\u2014selected local treatment methods and their effectiveness. Reumatol\/Rheumatol 55:305\u2013313","journal-title":"Reumatol\/Rheumatol"},{"key":"4269_CR36","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00383-003-1020-7","volume":"19","author":"T Doede","year":"2003","unstructured":"Doede T, Wollina U, Hindermann W, Schier F, Bondartschuk M (2003) Pansclerotic morphea in childhood: a case report. Pediatr Surg Int 19:406\u2013408","journal-title":"Pediatr Surg Int"},{"key":"4269_CR37","first-page":"iii52","volume":"45","author":"C Sunderk\u00f6tter","year":"2006","unstructured":"Sunderk\u00f6tter C, Kuhn A, Hunzelmann N, Beissert S (2006) Phototherapy: a promising treatment option for skin sclerosis in scleroderma? Rheumatology 45:iii52\u2013iii54","journal-title":"Rheumatology"},{"key":"4269_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1365-2133.1997.tb14925.x","volume":"136","author":"C Gruss","year":"1997","unstructured":"Gruss C, Stucker M, Von Kobyletzki G, Schreiber D, Altmeyer P, Kerscher M (1997) Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol 136:293\u2013294","journal-title":"Br J Dermatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04269-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-019-04269-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-019-04269-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T11:44:41Z","timestamp":1721043881000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-019-04269-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4269"],"URL":"https:\/\/doi.org\/10.1007\/s00296-019-04269-w","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,5]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research has been approved by the Human Research Ethics Committee by The Royal Children\u2019s Hospital, Melbourne, Australia (HREC 38167).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the parents of the presented patient for publication and for clinical photography to be used for research purposes.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}